Cargando…
Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors
[Image: see text] SARS-CoV-2 encodes two viral cysteine proteases, the main protease (M(pro)) and the papain-like protease (PL(pro)), both of which are validated antiviral drug targets. PL(pro) is involved in the cleavage of viral polyproteins as well as immune modulation by removing ubiquitin and i...
Autores principales: | Ma, Chunlong, Wang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806001/ https://www.ncbi.nlm.nih.gov/pubmed/35178512 http://dx.doi.org/10.1021/acsptsci.1c00240 |
Ejemplares similares
-
Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor
por: Tan, Haozhou, et al.
Publicado: (2022) -
Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor
por: Tan, Haozhou, et al.
Publicado: (2022) -
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
por: Ma, Chunlong, et al.
Publicado: (2022) -
In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease
por: Huynh, Tien, et al.
Publicado: (2021) -
Can Papain-like Protease Inhibitors Halt SARS-CoV-2
Replication?
por: Maiti, Biplab K
Publicado: (2020)